

## PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Suzhou Novartis Pharma Technology Co., Ltd.	08/30/2012
RECEIVING PARTY DATA	
Name:	Novartis AG
Street Address:	Lichtstrasse 35
City:	Basel
State/Country:	SWITZERLAND
Postal Code:	4056
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13603990
CORRESPONDENCE DATA	
Fax Number:	6178713392
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	6178713105
Email:	susan.dillon@novartis.com
Correspondent Name:	Novartis Institutes for BioMedical Resea
Address Line 1:	220 Massachusetts Avenue
Address Line 4:	Cambridge, MASSACHUSETTS 02139
ATTORNEY DOCKET NUMBER:	PAT054774-US-NP
NAME OF SUBMITTER:	Susan M. Dillon
Total Attachments: 7 source=54774_Assignment_SNPT to NAG#page1.tif source=54774_Assignment_SNPT to NAG#page2.tif source=54774_Assignment_SNPT to NAG#page3.tif source=54774_Assignment_SNPT to NAG#page4.tif source=54774_Assignment_SNPT to NAG#page5.tif source=54774_Assignment_SNPT to NAG#page6.tif source=54774_Assignment_SNPT to NAG#page7.tif	

CH \$40.00 13603990

# 公 证 书

中华人民共和国上海市东方公证处

## ASSIGNMENT

This Assignment Agreement is entered into by and between Suzhou Novartis Pharma Technology Co., Ltd., #18 Tonglian Road, Riverside Industrial Park, Changshu Economic Development Zone, Changshu / Jiangsu Province 215537, China, a company organized under the laws of China, and NOVARTIS AG, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Suzhou Novartis Pharma Technology Co., Ltd. does hereby sell, assign and transfer to NOVARTIS AG and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

### BENZOTHAZOLONE COMPOUND [Patent Application PAT054774]

and filed in the \_\_\_\_\_ Office on \_\_\_\_\_, 20\_\_\_\_ and accorded Application Number \_\_\_\_\_ and/or filed as a PCT International Application on September 06, 2011 and accorded International Patent Application Number PCT/CN2011/079379; and/or filed in the United States Patent and Trademark Office on \_\_\_\_\_, 20\_\_\_\_ and accorded Application Number \_\_\_\_\_;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by Suzhou Novartis Pharma Technology Co., Ltd. if this sale, assignment and transfer had not been made.

Suzhou Novartis Pharma Technology Co., Ltd. hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

Suzhou Novartis Pharma Technology Co., Ltd. hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.


Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.


This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 30 day of August, 2012

Suzhou Novartis Pharma Technology Co., Ltd.

BY  L.S.




Executed this 05 day of September, 2012

NOVARTIS AG

BY  L.S.  
**Ella Rutschmann**  
Authorized signatory

NOVARTIS AG

BY  L.S.  
**Reto Halbeisen**  
Authorized signatory

# 公 证 书

(2012)沪东证外字第 46269 号

申请人：苏州诺华制药科技有限公司

住所：江苏省常熟市经济开发区沿江工业园通  
联路 18 号

法定代表人：CHRISTOPHER DAVID SNOOK

委托代理人：冯向东，男，一九六七年十一月  
二十六日

公民身份号码：370202196711265457

公证事项：签名（印鉴）


兹证明苏州诺华制药科技有限公司的委托代理人冯  
向东于二〇一二年八月三十日来到我处，在本公证员面  
前，在前面的外文文件上签名并加盖公司印章。

中华人民共和国上海市东方公证处

公 证 员

沈宇明

二〇一二年八月三十日



1127612854

Translation

NOTARIAL CERTIFICATE

(2012)H.D. Z.W.Z.No.46269

Applicant:

Suzhou Novartis Pharma Technology Co., Ltd.

Domicile: No. 18, Tonglian Rd., Riverside Industrial Park,  
Changshu Economic Development Zone, Jiangsu Province

Legal Representative: CHRISTOPHER DAVID SNOOK

Entrusted Agent: FENG Xiangdong, male, born on November  
26, 1967, Citizen ID No.: 370202196711265457

Notarized Matter: Signature (Seal)

This is to certify that FENG Xiangdong, the entrusted agent  
of Suzhou Novartis Pharma Technology Co., Ltd., came to  
this office and affixed signature and company seal to the  
foregoing foreign language document before the notary  
public on August 30, 2012.

SHEN Yuming (Seal)

Notary Public

The People's Republic of China

Shanghai Oriental Notary Public Office

(Seal)

August 30, 2012

1127595497

# ATTESTATION

I, the undersigned Civil Law Notary in Basel, Switzerland, Dr. Matthias Staehelin, certify herewith that the signatures attached heretofore are the genuine signatures of **Ms. Ella Rutschmann**, citizen of Lotzwil, Switzerland, residing in Basel, Switzerland; and of **Mr. Reto Halbeisen**, citizen of Wahlen/BL, Switzerland, residing in Laufen, Switzerland; both acting for **Novartis AG**, in Basel, Switzerland, both as proxy holders and both with joint signature.

The authenticity of the signatures was established by means of comparison.

BASEL, Switzerland, this 19<sup>th</sup> (nineteenth) day of September 2012 (two thousand and twelve)

M. Staehelin, Notar

Dr. M. Staehelin  
Notar

Leg.Prot.Nr.: 1666/2012